BDP1 and ovarian carcinoma: Thus, we sought to determine if BDP1 is a potential predictive biomarker in ovarian cancer, In Figure 5, we analyzed BDP1 expression at twelve‐month relapse‐free survival in patients treated with platin (Figure 5A), taxane (Figure 5B), or combination therapy (Figure 5C).